Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Dec 23, 2020 11:35am
171 Views
Post# 32169432

The Ever Useful Dr. Lilge takes on Mask Decontamination

The Ever Useful Dr. Lilge takes on Mask DecontaminationAnd, as usual, his research keeps in mind the needs of those in poorer countries.

Journal of BIOPHOTONICS

Inside Cover

Lothar Lilge  Angelica Manalac  Madrigal Weersink  Fynn Schwiegelshohn  Tanner YoungSchultz  Abdallatif Satti Abdalrhman  Chengjin Wang  Aldrich Ngan  Frank X. Gu  Vaughn Betz  Ron Hofmann

First published: 22 December 2020

image

FULL ARTICLE

1 INTRODUCTION
 
Rapid local or global outbreaks of disease, such as SARS, Ebola and COVID19 caused by SARSCoV2, cannot be forecast despite the general knowledge that they will sporadically occur. Health care providers are particularly at risk during such outbreaks. For example, out of the 8096 reported cases during the 2002 to 2004 SARS outbreak, (21%) were health care workers, as were 221 of the 3956 fatalities in Sierra Leone during the 2019 to 2020 Ebola outbreak. The death rate associated with SARSCoV2 induced COVID19 ranges from 1.3% (Russia) to 15.5% (France) June 8, 20203 and an average mortality rate of 3.7%, underscoring the need for a very high level of protection for health care workers. Hence, the use of N95 disposable filtering facepiece respirators (FFR) is restricted to front line health care professionals in most North American jurisdictions. Regular face masks are recommended for the broader public to reduce the infection rate further.
 
The current COVID19 pandemic has severely stressed supplies of personal protective equipment (PPE), including N95 FFR (N95 FFRs). In response, healthcare facilities worldwide are forced to extend the use or reuse of their N95 FFRs. Few options can be adopted for N95 FFR reuse. The US Food and Drug Administration (FDA) emergency use authorization (EUA) guidance states that vaporized hydrogen peroxide gas plasma or hydrogen peroxide vapor (HPV) can be used for FFR decontamination if various conditions are satisfied, such as being free of visible damage and visual soil/contamination.5 Due to postprocessing form loss, vaporized hydrogen peroxide gas sterilization is not authorized for use with respirators containing cellulosebased or paper materials. Moreover, these techniques are not readily available in some middle and lowincome countries. Among the alternative methods, ultraviolet light germicidal irradiation (UVGI) is promising and is recommended by the US centers for disease control and prevention.
 
...........................................
 
4 CONCLUSION
 
UVGI is a reasonable approach for FFR decontamination to extend a respirator's usable lifetime when supply chains are restricted during public health emergencies. Both the investment costs and environmental impact are low. Operator exposure to harmful UV radiation and ozone can be minimized by simple technical safety measures. However, to achieve consistent, fast and complete decontamination, the photonsource positions need to be paired to the respirator shape, and the optical properties of the FFR model to be irradiated needs to be determined at the UVGI wavelength, to establish the minimum required exposure time based on photon distribution simulations as described here.
<< Previous
Bullboard Posts
Next >>